Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.

Saved in:
Bibliographic Details
Title: Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.
Authors: Covington N; College of Charleston, Charleston, South Carolina., Luetkemeyer AF; University of California San Francisco, San Francisco, California, USA., Imperial MZ; University of California San Francisco, San Francisco, California, USA., Dawson R; University of Cape Town, Cape Town, South Africa., Cramer Y; Frontier Science Foundation, Brookline, Massachusetts., Rosenkranz S; Frontier Science Foundation, Brookline, Massachusetts., Swindells S; University of Nebraska Medical Center, Omaha, Nebraska., Gelmanova I; National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA., Avihingsanon A; Thai Red Cross AIDS Research Centre, Bangkok, Thailand., Arduino RC; McGovern Medical School at UTHealth, Houston, Texas, USA., Samaneka W; University of Zimbabwe, Harare, Zimbabwe., Dooley KE; Vanderbilt University Medical Center., Savic R; University of California San Francisco, San Francisco, California, USA., Podany AT; University of Nebraska Medical Center, Omaha, Nebraska., Haas DW; Vanderbilt University Medical Center.; Meharry Medical College, Nashville, Tennessee, USA.
Source: Pharmacogenetics and genomics [Pharmacogenet Genomics] 2025 Jun 01; Vol. 35 (4), pp. 140-144. Date of Electronic Publication: 2025 Feb 12.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101231005 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-6880 (Electronic) Linking ISSN: 17446872 NLM ISO Abbreviation: Pharmacogenet Genomics Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-6880
DOI:10.1097/FPC.0000000000000562